Long-term follow-up of non-HIV Kaposi's sarcoma treated with low-dose recombinant interferon alfa-2b

Cunha, C. S. Costa da

doi:10.1001/archderm.132.3.285

Cited by 39 publications

(16 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Age, gender, duration of the disease or previous treatments did not affect the results. Whereas in AIDS-related Kaposi’s sarcoma patients become refractory to IFN [1], this was not observed in our patients with classic Kaposi’s sarcoma but was observed in 1 of 16 patients described by costa da Cunha et al [3]. …”

Section: Discussioncontrasting

confidence: 44%

See 1 more Smart Citation

Classic Kaposi’s Sarcoma: Low-Dose Interferon Alfa Treatment

Tur

Brenner²

1998

Dermatology

View full text Add to dashboard Cite

Background: Classic Kaposi’s sarcoma, a rare form of cancer, has no definitive cure. A beneficial effect of low-dose interferon (IFN) alfa was indicated by some case reports. In the present report, we summarize the results of our experience with subcutaneous low-dose IFN alfa treatment of 11 patients with extensive classic Kaposi’s sarcoma and review the literature. Design: Eleven patients, 56–96 years old, were treated: 10 men, 1 woman, 3 of whom had an associated malignancy. Subcutaneous injections of IFN alfa were given, starting with 3 million units 5 times a week, and modified according to side effects and response after 2 weeks (2–6 million units, 3–6 times a week). This treatment was continued for 6 months, except for 1 patient who died after 4 months and another who stopped treatment at 4 months due to surgery but was treated again after recurrence. Treatment was continued after 6 months when a partial response was noted, but further improvement was desired (1 patient). Results: In 9 out of the 11 patients, initial response was noted after 3–13 weeks of treatment. This was manifested by a reduction of lesion size and fading of color, leading to a partial resolution. Maximum response was achieved after 4–6 months. Remission lasted 4–72 months. Recurrences were retreated, with additional remissions after only 5–8 weeks of treatment. Side effects included fever and fatigue, which were overcome by dose reduction. Conclusion: Whereas in AIDS-related Kaposi’s sarcoma patients become refractory to IFN, this was not observed in our patients with classic Kaposi’s sarcoma. Moreover, unlike AIDS-related Kaposi’s sarcoma, continuous treatment was not needed in classic Kaposi’s sarcoma, and recurrences were responsive to retreatment.

show abstract

Section: Discussioncontrasting

confidence: 44%

“…Recurrences were successfully treated with lower IFN doses. Furthermore, Costa da Cunha et al [3] reported that relapse after IFN treatment was delayed and very limited, and in several patients did not even require an additional treatment.…”

Section: Discussionmentioning

confidence: 99%

Classic Kaposi’s Sarcoma: Low-Dose Interferon Alfa Treatment

Tur

Brenner²

1998

Dermatology

View full text Add to dashboard Cite

show abstract

“…In most cases it progresses slowly and even some spontaneous remissions have been described in 2% of the cases [1]. However, its course can also progress rapidly and result in death within a few weeks [2]. Koebner phenomenon, also called the isomorphic response, refers to the reoccurrence of lesions in some previously intact incision sites following removal of tumour, and may also be present [3].…”

Section: Discussionmentioning

confidence: 99%

Disseminated classic Kaposi's sarcoma

et al. 2007

View full text Add to dashboard Cite

Kaposi's sarcoma (KS) is characterised by proliferation of vascular endothelial and lymphoreticular cells, frequently with a multicentric expression developed from a single node and evolving to multiple cutaneous lumps or plaque-like appearance. Four types of KS with similar histological patterns have been described in terms of their clinical and epidemiological features: classic KS, endemic (African) KS, iatrogenic KS and epidemic (AIDS-related) KS. The differences in clinical features are quite relevant: classic KS is usually limited to the lower extremities; whereas immunodeficiency-related diseases frequently involve several organs. A case of a 67-year-old woman with metastatic KS and unproven immunodeficiency is presented.

show abstract

“…Prior to the use of pegylated liposomal doxorubicin (PLD), various chemotherapeutic agents were tested as first-and second-line treatments for CKS in small studies, with promising results [6][7][8][9][10]. Because of the rarity and distribution of cases, only one randomized trial in patients with CKS has been published [7].…”

Section: Systemic Therapymentioning

confidence: 99%

“…Although because of few numbers of patients, few trials have been published, and most have been retrospective studies [6][7][8][9][10]. Considering that CKS affects an elderly population, it is important to have new chemotherapeutic regimens that act rapidly, have limited side effects, and are available to be used for long periods.…”

Section: Introductionmentioning

confidence: 99%

Update on classic Kaposi sarcoma therapy: New look at an old disease

Lorenzo

2008

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

Long-term follow-up of non-HIV Kaposi's sarcoma treated with low-dose recombinant interferon alfa-2b

Cited by 39 publications

References 23 publications

Classic Kaposi’s Sarcoma: Low-Dose Interferon Alfa Treatment

Classic Kaposi’s Sarcoma: Low-Dose Interferon Alfa Treatment

Disseminated classic Kaposi's sarcoma

Update on classic Kaposi sarcoma therapy: New look at an old disease

Contact Info

Product

Resources

About